SPOnSORSHIP - SourceMedia

Spo
nsorship
m&a MID-MARKET
mid-market AWARDS
awards
M&A
The mid-market awards features the Deals and Dealmakers who domineered 2013. Middle-Market
dealmakers flock to the March issue for an in-depth read on the deals that transcended a sluggish economic
recovery and the uncertainty of a hotly-contested presidential race that shone a bright light on private equity.
Reach thousands of highly engaged dealpros through this integrated marketing sponsorship.
M&A Home Page
PACKAGE OVERVIEW
Leaderboard
■■
wallpaper
wallpaper
Pushdown
■■
■■
■■
Home Page Takeover — co-branded & exclusive
Awards Page — co-branded & exclusive
Enewsletter Blast — exclusive
Mergers & Acquisitions’ March Issue — co-branded
PACKAGE DETAILS
Sponsor Brand Placements
■■
M&A Awards Page
M&A Awards Page ( 1 year)
•• 88x31 Logo
•• 300x250 Medium Rectangle
ENewsletter
■■
Mergers & Acquisitions Magazine (1 month)
•• 1x Insertion in March Issue 4/C Full Page
■■
88x31
March Bonus Distribution
•• 3/13 ACG San Francisco M&A Conference
•• 3/6 ACG Texas Capital Connection
•• 3/20-21 ACG Rocky Mtn. Corporate Growth Conference
•• 3/20-21 ACG NY/Utah Dealmakers Ski & Board Conference
Rectangle
468x60 BANNER
■■
M&A Monday Monitor eNewsletter (1 Month)
•• 468x60 Full Banner
■■
Dealmaker Portal
•• 728x90 Leaderboard
Co-Branded Sponsorship
■■
MARCH 2012
THE OFFICIAL PUBLICATION OF
Cover Story
Craig Stevenson’s
Diamond S Shipping
Takes Home
Deal of the Year
The
THEMIDDLEMARKET.COM
001_MAJMar12 1
M&A MID-MARKET AWARDS
DEALMAKER OF THE YEAR
Dr. Roger Perlmutter
A
can bring to this company the kind of
proach involves using an oncolytic virus,
mgen, the world’s largresources it would really need to do
a virus that has been reprogrammed into
est stand-alone biotech
effective large-scale clinical trials,” Perla cancer-fighting agent that attacks only
company, made the
mutter told Luke Timmerman, national
cancerous cells, leaving healthy cells unyear’s smartest middlebiotech editor of the Xconomy blog, in
damaged.
market M&A play in
an interview the day after the deal was
“OncoVex has demonstrated enthe pharmaceutical industry. Competiannounced. “Not to discredit what they
couraging anti-tumor activity in clinical
tors spent multiple billions of dollars
have already achieved, which is considstudies for the treatment of melanoma
on acquisitions, such as Gilead Sciences
erable. But we have a bit more muscle.”
and head and neck cancer, and BioVex
Inc.’s $10.4 billion of Pharmasset Inc. for
Amgen’s
M&A
is currently enrolling
its hepatitis C treatment. But Amgen, of
muscles
continue
patients into pivotal
Thousand Oaks, Calif., bought BioVex
to get a workout.
Phase 3 trials in both
Group Inc., of Woburn, Mass., for a mere
Earlier this year, the
indications,” Perlmut$425 million up-front payment, with the
company agreed to
ter said when anpledge to pay up to $575 million, tied to
acquire Micromet for
nouncing the deal
milestones. By structuring the deal with
about $1.16 billion.
last January. “Amgen
contingent value rights payments, AmFounded in Germany,
is particularly excited
gen hedged its bets on the target’s innowith an R&D center
about joining with
vative cancer vaccine, OncoVex, which
in Munich and headBioVex and its talhas not yet received FDA approval. If the
quarters in Rockville,
ented staff to focus
treatment succeeds, it will be a windfall
Md., Micromet makes
on advancing this
for Amgen, and the BioVex deal will be
blinatumomab, an anlate-stage investigaperceived as a great bargain.
tibody being tested in
tional therapy, with
The man behind the deal was Rogclinical trials of peothe hope of bringing
er Perlmutter, Amgen’s executive vice
ple with acute lymit to market within the
president, research and development.
phoblastic leukemia
next few years.”
Perlmutter holds M.D. and Ph.D. deDr. Roger Perlmutter
and non-Hodgkin’s
grees from Washington
lymphoma.
University, and was a
PLUS
It looks as if Micromet will be
professor of immunolWe can bring to BioVex the kind of
ogy at the University of
resources it would really need to do Perlmutter’s swan song at Amgen.
Aged 59, he retired in February
Washington in Seattle.
effective large-scale clinical trials. but will serve as a consultant for
He left academia in 1997
another year.
to join Merck and Co. In
Sean Harper, former senior vice presSpun out of University College of
2001, he arrived at Amgen, where he has
ident for global development, has sucLondon a decade ago, BioVex raised
been pushing the company to become
ceeded Perlmutter. CEO Kevin Sharer
$150 million from more than a dozen
more aggressive in developing anti-tu2/9/2012 1:22:17 PM
will also retire in May, with current presiventure capital groups.
mor drugs ever since.
dent Robert Bradway taking the reins.
To woo BioVex, Perlmutter emphaOncoVex has the potential to change
—Mary Kathleen Flynn
sized the vast resources of Amgen. “We
cancer treatment dramatically. The ap-
Full Page ad
MERGERS & ACQUISITIONS
024_MAJMar12 5
Plus, Your sponsorship of the M&A Mid-Market
Awards’ website will remain live until next year’s
call for submissions.
For more information, contact:
Q&A with BET Founder Robert L. Johnson
Gene Simmons Keynotes ACG San Francisco
24
TheMiddleMarket.com Home Page (1 month)
88x31 on the following:
•• Wall Paper Pillars
•• OPA Pushdown
Print
March 2012
2/9/2012 1:56:07 PM
Harry Nikpour, Publisher, Mergers & Acquisitions,
212.803.8638 ■ [email protected]